The purpose of this study is to investigate the maximum safe dose of an investigational medication in combination with another investigational treatment for patients with metastatic clear cell kidney cancer. Metastatic clear cell kidney cancer is a type of kidney cancer that has spread to other parts of the body.
Participants will receive a combination of the investigational treatments. The study will assess the response rate to this combination in patients who have not received prior therapy for their metastatic clear cell kidney cancer.
- Who can participate: Participants must be adults diagnosed with metastatic clear cell kidney cancer who have not received previous treatment for their condition. Other eligibility criteria include adequate organ function and no history of severe cardiovascular diseases.
- Study details: Participants will receive a combination of investigational treatments to assess their response. The study aims to find the maximum safe dose and activity of this combination.
